Purpose The increasing incidence of endometrial cancer (EC), in younger age at diagnosis, calls for new tissue-sparing treatment options. This work aims to evaluate the potential of imiquimod (IQ) in the treatment of low-grade EC. Methods Effects of IQ on the viabilities of Ishikawa and HEC-1A cells were evaluated using MTT assay. The ability of IQ to induce apoptosis was evaluated by testing changes in caspase 3/7 levels and expression of cleaved caspase-3, using luminescence assay and western blot. Apoptosis was confirmed by flow cytometry and the expression of cleaved PARP. Western blot was used to evaluate the effect of IQ on expression levels of Bcl-2, Bcl-xL, and BAX. Finally, the in vivo efficacy of IQ was tested in an EC mouse model. Results There was a decrease in EC cell viability following IQ treatment as well as increased caspase 3/7 activities, cleaved caspase-3 expression, and Annexin-V/ 7AAD positive cell population. Western blot results showed the ability of IQ in cleaving PARP, decreasing Bcl-2 and Bcl-xL expressions, but not affecting BAX expression. In vivo study demonstrated IQ's ability to inhibit EC tumor growth and progression without significant toxicity. Conclusions IQ induces apoptosis in low-grade EC cells in vitro, probably through its direct effect on Bcl-2 family protein expression. In, vivo, IQ attenuates EC tumor growth and progression, without an obvious toxicity. Our study provides the first building block for the potential role of IQ in the non-surgical management of low-grades EC and encouraging further investigations. 
INTRODUCTION
Endometrial cancer (EC) is the most common gynecological malignancy in developed countries (1, 2) . Obesity is identified as a major predisposition factor for EC with a rise in EC prevalence correlating with an increase in obesity rate (3) . It is further a known risk factor with obese women having a 2-5 fold higher incidence of EC (3) . For 2016, the American Cancer Society estimated that about 60,000 new cases of uterine cancers will be diagnosed and 10,470 deaths will occur Electronic supplementary material The online version of this article (doi:10.1007/s11095-016-1957-6) contains supplementary material, which is available to authorized users. (4, 5) . Based on etiology and histology, EC can be categorized into two subtypes. Type I endometrial cancer (endometrioid EC), is induced by an uncontrolled, increased exposure to estrogen (E2) over a prolonged period of time. EC is often preceded by lesions know as endometrial hyperplasia (EH) (2, (6) (7) (8) . Originally, Type I EC was considered as a disorder predominantly affecting postmenopausal women. However, more cases are now diagnosed in younger women and often are associated with obesity (9, 10) . Type I EC is usually well or moderately differentiated and has a good prognosis. Type II (serous EC), on the other hand, is E2 independent, more common in postmenopausal women, poorly differentiated, more aggressive, and carries an unfavorable prognosis (7, 8, 11, 12) . Most common molecular alterations found in Type I disease are microsatellite instabilities and mutations in PTEN, K-ras, and β-catenin (13) . On the other hand, mutations related to Type II include P53, HER-2 and the down regulation of Ecadherin (13) .
High E2 levels in Type I disease lead to an abnormal increase in endometrial glands proliferation rate (14) . The action of E2 on the endometrium is not limited to increasing glandular proliferation, but also includes the inhibition of apoptosis of endometrial cells (14) (15) (16) . Different mechanisms are involved in E2's anti-apoptotic effects. For example, E2 activate a number of cell survival pathways including Src/ERK, mitogen-activated protein kinases (MAPK), and serine-threonine kinase Akt/PKB pathways (17) (18) (19) . On the nuclear level, E2 increases the expression of the anti-apoptotic protein B-cell lymphoma/leukemia-2 gene (Bcl-2), resulting in a disturbance of its balance with the cancer suppressor gene Bcl-2-associated X protein gene (BAX) (17, 18, 20) . Higher expression levels of Bcl-2 are found in E2 driven tumors such as breast cancer, low-grade EC, as well as EH (21, 22) . This indicates that Bcl-2 is possibly involved in pre-neoplastic and neoplastic events leading to EC (21) .
Total abdominal hysterectomy is the standard therapy for EC. However, in a subset of patients with low-grade early stage disease such as women of reproductive age wishing to preserve their fertility or women who are poor surgical candidates, conservative management can be offered (23, 24) . Although progesterone shows efficacy in the conservative management of Type I EC, 30-35% of women with welldifferentiated tumors fail to respond to therapy or recur with the exact mechanisms of resistance to therapy unknown (24) (25) (26) (27) . For this particular subset of patients additional treatment options are needed. I m i q u i m o d ( I Q ) , a n u c l e o s i d e a n a l o g o f t h e imidazoquinoline family, was initially developed as an antiviral agent against Human Papilloma Virus for the treatment of genital and perianal warts (28, 29) . Recently, IQ was found to also exhibit antitumor effects against different malignancies such as prostate and urothelial cell carcinoma (30, 31) . Clinical trials further demonstrated that IQ is effective in the treatment of vulvar, cervical, and vaginal intraepithelial neoplasias (32) (33) (34) . IQ exhibits antitumor activity presumably by inducing apoptosis through direct and indirect pathways (35) . By binding to Toll-like receptors (TLR) 7 and 8, IQ can indirectly induce apoptosis through cytokine-mediated stimulation of the immune system (28, 36) . Although the exact apoptotic effect of IQ is still unclear, recent studies demonstrated that IQ could induce apoptosis most probably through reducing levels of Bcl-2 or other members of the Bcl-2 family like Myeloid cell leukemia 1 (Mcl-1) (37, 38) . Thus, in this work, we evaluated IQ's anticancer effect by focusing on its apoptotic potential in human EC cells in vitro, and also studied IQ's efficacy in vivo using an EC xenograft mouse model.
MATERIALS AND METHODS

Materials
Imiquimod was purchased from Invivogen (CA, USA). MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide was purchased from Invitrogen (OR, USA). Annexin-V conjugated to allophycocyanin (APC), 7-Aminoactinomycin D (7-AAD), and Annexin Binding Buffer were purchased from Life Technologies (NY, USA). Immunoblotting detection was conducted using the following antibodies: Anti-beta actin (Sigma, A5541), Anti Caspase-3 (Cell Signaling, 9662S), Anti-PARP (Cell Signaling, 9542 T), Anti-Bcl-2 (Cell Signaling, 2876S), Anti -Bcl-xL (Abcam, GR192701-3) and Anti-BAX (Abcam, GR151406-1).
Cell Culture
Ishikawa cells (well-differentiated human endometrial adenocarcinoma cell) were generously provided by Dr. BaeJump, University of North Carolina. HEC-1-A cells (moderately differentiated human adenocarcinoma) were purchased from American Type Cell Culture Collection (ATCC, Manassas, VA). Ishikawa cells were cultured in Minimum Essential Medium Eagle (Sigma, MO, USA) supplied with 1% Non-Essential Amino Acids (NEAA), 5% Fetal Bovine Serum (FBS),100 units/mL penicillin, and 100 μg/mL streptomycin. HEC-1-A cells were cultured in McCoy's 5A medium (ATCC, Manassas, VA) supplied with 5% FBS, and 100-units/mL penicillin, 100 μg/mL streptomycin. Cells were grown and routinely maintained at 37°C in 10 cm 2 culture dishes.
Animals
Six-to-eight-week old female Nu/Nu athymic mice were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Animals were housed at the Center for Comparative Medicine Animal Facility at the University of Utah. Animals were treated following approval of the Institutional Animal Care and Use Committee (IACUC) protocols and in strict adherence to their guidelines.
Cell Viability Assay
To determine the effect of IQ on cell viability, Ishikawa and HEC-1A cells were seeded in 96-well plates at a density of 5 × 10 3 cells/well and incubated for 24 h in 100 μL media/ well. Serial dilutions of IQ (0-100 μg/mL) were added to cells. At predetermined time points, 20 μL of 2.5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in PBS was added to the cells and cell were further incubated at 37°C. After 4 h, MTT solutions were completely removed and 100 μL DMSO was added to solubilize formazan crystals. Absorbance was measured at 540 nm using Spectramax 250 microplate reader (Molecular device, CA, USA) and percent viability was calculated.
Caspase Levels Measurements
The activation of Caspases 3/7 after IQ exposure was measured using Caspase 3/7-Glo (Promega, WI, USA) following manufacturer's protocol. Briefly, cells were seeded at a density of 5 × 10 3 cells/ well in an opaque-wall 96 well plate with a solid bottom. Cells were treated with IQ for 12, 24, 48, and 72 h. Caspase 3/7-Glo reagent was added to wells containing cells, the plate was shaken at 300 RPM for 30 sec, and incubated at room temperature for 45 min. Luminescence was measured using Infinite® M1000 PRO, and analyzed using Tecan i-control 1.10.4.0 software.
Flow Cytometry
Annexin-V Assay
Ishikawa and HEC-1A cells were assayed for Annexin-V binding after 72 h of exposure to IQ as described (39) . At 72 h, cells were harvested, suspended in 500 μl Annexin binding buffer, (ABB) and incubated with 5 μl/mL Annexin-APC (Annexin-V conjugated to allophycocyanin for 15 min. The incubated treated cells and controls were analyzed using the FACSCanto-II (BD-BioSciences) at the University of Utah Core Facility. APC was excited with 635 nm laser and detected at 660 nm.
7-AAD Assay
Ishikawa and HEC-1A cells were exposed to IQ for 72 h, then suspended in 500 μl ABB. Cells were then stained by adding 1 μL/ mL of 7-aminoactinomycin D (7-AAD), and incubated in ice for 45 min. Treated as well as control cells were analyzed using the FACSCanto-II (BD-BioSciences). 7-AAD was excited with a 488 nm laser and detected at 660 nm. Spectral compensation was set by using cells single stained with APC alone, 7-AAD alone, or no stain.
Western Blot
HEC-1A or Ishikawa cells were plated in 10 cm 2 culture dishes, and then treated with IQ for 24, 48, and 72 h. W h o l e c e l l l y s a t e s w e r e p r e p a r e d u s i n g Radioimmunoprecipitation assay (RIPA) buffer (SigmaAldrich, MO, USA), and protein was quantified using DC Protein Assay Kit (Bio-rad, CA, USA). Cell lysates of IQ treated, and control cells (20 μg/well) were loaded in 4-20% Mini-Protean TGX Gels (Bio-rad, CA, USA), underwent electrophoresis, and transferred to a PVDF membrane (Biorad, CA, USA). After blocking the membrane with 5% (w/v) skimmed milk prepared in Tris-buffered saline and Tween 20 (TBS-T), blots were incubated with primary antibodies prepared based on manufacturer's recommendation overnight at 4°C. Membranes were then washed and incubated with the suitable secondary antibody, horseradish peroxidase-coupled anti-rabbit or anti-mouse antibody. Bands were visualized using Western Bright ECL Kit for 5000 cm 2 Membrane and Blue Basic Autoradiography Film (Bioexpress, CA, USA).
In vivo Evaluation of IQ in Endometrial Cancer Xenograft Mouse Model
Tumor chunks originally generated from human endometrial cancer cell line (HEC-1A) were dissected to ≈ 3-4 mm 3 and implanted subcutaneously into the lower right flank of 6-8 week old female nu/nu athymic mice. Two weeks after tumor implantation, animals were randomized into either vehicle (n = 5) or IQ treated group (n = 14). Peritumoral injection of 100 μL of (1 mg/mL) IQ or vehicle (sterile water for injection) was carried out three times a week for 21 days. Tumor volume was measured using the following formula:
, were (L) corresponds to the length and (W) to the width of the tumor. Animals were sacrificed 24 h after the last injection, and tumors were trimmed, fixed in 10% formalin for 48 h, and then dehydrated in 70% ethanol. Tissues were analyzed at the Associated Regional and University Pathologists (ARUP) at the University of Utah. Hematoxylin and Eosin stains (H&E) of representative tissue slides were evaluated using light microscopy at the Department of Pathology, University of Utah by two independent pathologists.
Statistical Analysis
Statistical analysis and plotting graphs were performed using GraphPad Prism software (GraphPad Software Inc. San Diego, CA). All experiments are conducted in triplicate unless otherwise indicated. Results are expressed as mean ± SD, and P < 0.05 was considered significant. Student t-test and Oneway ANOVA with Tukey's post hoc test were applied to compare the different treatment groups and controls.
RESULTS
IQ Impairs the Viability of EC Cells
We monitored the effect of IQ on Ishikawa and HEC-1A cells viability at an IQ concentration range of (0-100 μg/mL) for 24, 48, and 72 h. Results suggest that both cell lines are sensitive to IQ treatment, but differ in time to maximum response. Ishikawa cells exhibited a dose-dependent decrease in cell viability that was apparent at 24 h post-treatment, while the decrease in HEC-1A cell viability was more pronounced at 48 h post treatment (Fig. 1a and b) . IC-50s at 24, 48, and 72 h were 53.85 ± 3.6, 22.85 ± 3, and 15.98 ± 2.6 for Ishikawa cells and 96.49 ± 9, 56.48 ± 5, and 30.08 ± 3.4 for HEC-1A cells respectively. The effect of IQ on Ishikawa and HEC-1A cells was also confirmed using sulforhodamine B colorimetric assay ( Figure S1 ) (40) .
An Increase in Caspase-3/7 Activity and Cleaved caspase-3 Expression in Cells After IQ Treatment
To test our hypothesis -IQ is capable of inducing apoptosis in low-grade endometrial cancer -caspase 3/7 activity was measured after treating cells with ≈ 2 folds the IC50 (25 μg/mL for Ishikawa cells and 50 μg/mL HEC-1A cells) for 12, 24, 48, and 72 h. Ishikawa cells showed an increase in caspase-3/7 activity within 12 h of IQ treatment (Fig. 2a) . HEC-1A cells, in contrast, showed an increase in caspase 3/7 at 48 h of therapy and after a slight initial decrease during the first 24 h of drug exposure (Fig. 2b) . The delayed onset of caspase activity to IQ for cells is consistent with cell viability results.
The activation of caspase-3 was also analyzed using western blot. Activated caspase-3, denoted by a higher expression of cleaved caspase-3, was found with IQ treated cells. Cleaved caspase-3 was detected at 48, and 72 h in Ishikawa and HEC-1A cells after IQ treatment, respectively ( Fig. 2c and d) and (Figure S2, A) .
IQ Boosts Annexin-V and 7-AAD Positive Cell Numbers and Induces PARP Cleavage
To confirm the capability of IQ to induce apoptosis in EC cells, both flow cytometry (using 7-AAD and Annexin-V staining) and the expression of cleaved PARP were conducted. Figure 3a and b showed that both Ishikawa and HEC-1A cells had an increase in 7-AAD and Annexin-V positive cell populations after IQ treatment compared to untreated cells. Consistent with these results, western blot analysis ( Fig. 4a and b) and ( Figure S2, B) , depicted an increase in cleaved PARP expression in both cell lines after IQ treatment.
The Expression of Bcl-2 and Bcl-xL in Ishikawa and HEC-1A Cells are Reduced by IQ
The effect of IQ on expression levels of the pro-survival proteins Bcl-2 and Bcl-2 homologue B-cell lymphoma extra-large (Bcl-xL), and the pro-apoptotic protein BAX were evaluated using western blot. We detected a decrease in the expression of Bcl-2 and Bcl-xL over time in both cell lines; however, BAX expression seemed to remain unaffected ( Fig. 5a and b) and ( Figure S2, C) 
IQ Attenuates Tumor Growth in Endometrial Cancer Xenografts
A HEC-1A xenograft mouse model was utilized to evaluate the in vivo safety and efficacy of IQ in treating EC. We began IQ or vehicle administration 2 weeks after tumor implantation (average tumor volume of 50 mm 3 ). Animals total body weights as well as tumor volumes were measured three times a week before, and throughout the course of therapy. We observed that IQ prevented tumor growth and progression in vivo, in contrast to a continuous increase in mean tumors size in vehicle treated mice. The difference in mean tumor sizes before and after IQ therapy was not statistically significant. However, a significant difference present between tumors sizes before and after treatment in vehicle-treated group (Fig. 6a) . Histopathological evaluation of excised tumors after IQ treatment showed extensive inflammatory infiltration composed of neutrophils and lymphocytes percolating among malignant cells. On the other hand, vehicle treated tumors demonstrating extensive tumor growth and no inflammatory infiltrate is recognized. (Fig. 6b) . Animal weights through the course of therapy show no significant difference between IQ and vehicle-treated mice (Fig. 6c) .
DISCUSSION
EC remains one of the most diagnosed gynecological cancer with 25% of cases occurring in women under the age of 40 (41) . In addition to progesterone (P4) or progestins, gonadotropin releasing hormone (GnRH) agonists and aromatase inhibitors are often used as means of conservative therapy and are suggested in recurrent cases or for cases refractory to progestins (42) . Although initial reports were promising, GnRH only exhibited low response rates in cases with previous exposure to P4 (43) . Also, the prolonged use of GnRH and aromatase inhibitors can lead to symptoms of menopause such as bone loss, osteoporosis, and endometrial atrophy (44) . Based on its successful use in ovarian cancer, Poly (ADPribose) polymerase (PARP) inhibition recently also found its way into the treatment of EC. This approach is based on PARP inhibitors exhibiting efficacy in cancers deficient in DNA repair genes, such as ovarian and breast (45, 46) . It is known that up to 80% of endometrial cancers are associated with PTEN deficiency (13) . PTEN deficient tumors exhibit the loss in Rad51, a key gene involved in the repair of DNA double-stranded breaks (47) . Recently published findings report that PARP inhibitors were found less effective when higher levels of circulating E2 (hyperestrogenism) are present as found in many Type I EC patients (48) . Therefore, it is imperative to identify new agents and targets capable of conservatively managing in lower grade EC.
In this study, we evaluated the potential of IQ in the management of low-grade endometrial cancer in vitro as well as in vivo. Our results indicate that IQ is capable of inducing apoptosis in low-grade EC cells. This induction is mostly due to the inhibitory effect of IQ on the expression of the Bcl-2 and Bcl-xL proteins. Importantly, IQ is also capable of inhibiting tumor progression in vivo in EC bearing mice.
Although both, Ishikawa and HEC-1A were sensitive to IQ, the delay in HEC-1A cell response to most IQ concentrations within the first 24 h of treatment could be due to an initial inhibitory effect of IQ on cell proliferation (cytostasis). Two scenarios can possibly follow the inhibition of cell growth by an anticancer drug; cells could either recover and acquire resistance or suffer cytotoxicity (49) . Cytotoxicity preceded by cytostasis was seen previously with some anticancer agents such as vincristine and paclitaxel (50, 51) . The decrease in HEC-1A cell viability in a dose-dependent manner after longer incubation times (48 and 72 h of treatment) suggests that cytotoxicity is eventually the end result in cells exposed to IQ. This data also suggests that well-and moderately-differentiated EC cells may respond differently to the same anti-cancer agent.
The goal for many anti-cancer agents is the induction of apoptosis by damaging DNA (49) . In our results, IQ was able to affect caspase 3/7 activity, implicating IQ involvement in a mechanism that promotes apoptosis in EC. The direct increase in caspase 3/7 within 12 h of Ishikawa cells exposed to IQ suggests that the agent is capable of inducing apoptosis in well-differentiated EC cells shortly after exposure. The initial lower caspase activity found in HEC-1A cells relative to control cells implies that cells were quiescent Therefore, cells were not able to proliferate before undergoing apoptosis as evidenced by an increase in caspase 3/7 within 48 h of treatment (52) . The significant increase in Annexin-V and 7-AAD positive cell populations identified by flow cytometric analyses, as well as cleavage of PARP, validate our findings that IQ harbors potential apoptosis inducing capabilities in EC. To date the antitumor effect of IQ has been postulated to act mostly through a tumor-directed immune response, mediated via TLR 7 and 8 (28) . However, our results document a direct, apoptotic effect of IQ independent of these receptors (30, 36, 53) . With the lack of immune cells in vitro we hypothesize that apoptosis induced in EC cells is related to the IQ effect on the expression of Bcl-2 proteins. Increased Bcl-2 expression in the endometrium correlates with hormonal stat u s s h o w i n g a n u p -r e g u l a t i o n b y E 2 ( 5 4 -5 6 ) . Histopathological analysis of 100 women with abnormal endometrial proliferation showed strongest Bcl-2 expressions in atypical EH and lower grades EC (57) . These results suggest the involvement of Bcl-2 in the progression of EH and in early EC, identifying Bcl-2 as a potential target for treatment (21) . Our data also suggest that IQ is capable of disturbing the Bcl-2/BAX ratio by altering Bcl-2 and Bcl-xL expression in lower grade EC cells (Ishiakwa, and HEC-1A), revealing the possible activation of the intrinsic apoptotic pathway.
In vivo IQ is well tolerated, as there was a non-significant difference in body weight between IQ and vehicle-treated mice. While IQ was capable of preventing tumor growth in mice, treated tumors also exhibited leukocytic infiltration within the tumor milieu. Thus, the antitumor effect of IQ in vivo might involve additional mechanisms, including the stimulation of a tumor-directed immune response. Gynecological cancers including EC seem to be viable candidates for immunotherapy (58) . Recently, studies demonstrated that adding an immunotherapeutic to EC treatment regimens can be advantageous (59) . The administration of T cells stimulated by tumor lysate-pulsed autologous dendritic cells or a therapeutic cancer vaccine such as Wilms' tumor Gene 1-loaded dendritic cells are capable of activating the patient's own immune system by inducing a tumor-directed immune response (59, 60) . Further, lymphocytic tumor infiltration indicates a more favorable prognosis in some EC patients (61) . Hence, more detailed studies to further evaluate the exact role of IQ in initiating a tumor-directed immune response in EC are needed.
CONCLUSION
In conclusion, our results demonstrated that IQ attenuates the viability of well-and moderately-differentiated endometrial cancer cells, decrease the expression of Bcl-2 and Bcl-xL, activate caspase 3/7, cleaves PARP, and eventually induces apoptosis in vitro. In addition, local peritumoral administration of IQ is safe, well tolerated, and is capable of inhibiting tumor progression in an EC mouse xenograft model. Overall, our findings suggest that IQ holds promise in the treatment of lower grade endometrial cancers, encouraging further investigation to understand mechanisms of action in greater detail as well as to identify additional targets for conservative, nonsurgical management of these malignancies.
